Moderna shares are trading lower after the company's RSV vaccine showed 50% efficacy.
Portfolio Pulse from Benzinga Newsdesk
Moderna shares are trading lower after the company's RSV vaccine showed 50% efficacy.

June 26, 2024 | 3:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna shares are trading lower due to the company's RSV vaccine showing only 50% efficacy, which may have disappointed investors.
The lower-than-expected efficacy of the RSV vaccine likely disappointed investors, leading to a decline in Moderna's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100